Soon after introduction of bevacizumab, a humanized monoclonal anti-VEGF antibody, in clinical practice to prevent cancer growth and metastasis, proteinuria and hypertension were reported to occur as common complications [64]. The gene discussed is VEGFA; the disease is Hypertension.